Overview

A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Hypothesis: Different patients have different biomarkers, if doctors know about the biomarkers of patients; they may be able to prescribe a regimen that is better suited to the patient's specific needs. This is a pilot study. Here, we used whole exon sequencing and Integrated genomic network analysis to identify the biomarker or gene. We aimed to learn if the drug chosen based on biomarkers can help to control metastatic gastrointestinal cancer who had failed from all standard and available regimens.
Phase:
N/A
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Erlotinib Hydrochloride
Everolimus
Gefitinib
Imatinib Mesylate
Niacinamide
Sirolimus
Sorafenib
Sunitinib